Icon of the Instituts for Quality and Efficiency in Health Care

Dossier assessment

Axicabtagene ciloleucel (DLBCL and PMBCL, third line) – Benefit assessment according to §35a Social Code Book V

Status
Status: Commission completed
Project no.
A23-65
Last updated

Report documents

  1. Extract of dossier assessment

    Axicabtagene ciloleucel (DLBCL and PMBCL, third line) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF-Dokument, 504 kB, EN, PDF
    Download file : Extract of dossier assessment (PDF-Dokument, 504 kB, EN, PDF)

  2. Dossier assessment

    Axicabtagene ciloleucel (DLBCL and PMBCL, third line) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF-Dokument, 819 kB, DE, PDF
    Download file : Dossier assessment (PDF-Dokument, 819 kB, DE, PDF)

Dossier assessment

Indication:

Adults with relapsed or refractory diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma, after 2 or more lines of systemic therapy

Result of dossier assessment:
  • If high-dose therapy is an option: added benefit not proven
  • If high-dose therapy is not an option: added benefit not proven

Project details

Project no.
A23-65
Commission
Commission awarded on 03.07.2023 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Topic
Cancer
Note

After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.

Connected Projects

  1. Dossier assessment

    Axicabtagene ciloleucel (diffuse large B-cell lymphoma, second line) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A23-66
    Last updated

    Status: Commission completed

  2. Dossier assessment

    Axicabtagene ciloleucel (follicular lymphoma) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A23-63
    Last updated

    Status: Commission completed

  3. Dossier assessment

    Axicabtagene ciloleucel (B-cell lymphoma PMBCL) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V

    Project no.
    G18-19
    Last updated

    Status: Commission completed

  4. Dossier assessment

    Axicabtagene ciloleucel (B-cell lymphoma DLBCL) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V

    Project no.
    G18-18
    Last updated

    Status: Commission completed

  5. Dossier assessment

    Axicabtagene ciloleucel (diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma) - Assessment according to §35a (para. 1, sentence 11) Social Code Book V (expiry of the decision)

    Project no.
    G22-19
    Last updated

    Status: Commission completed

  6. Dossier assessment

    Axicabtagene ciloleucel (DLBCL and HGBL, second line) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A24-71
    Last updated

    Status: Commission completed

Contact

Press contact

+49 221 356850

press@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form

Print page